Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti-PD-1 in Metastatic Non-Small Cell Lung Cancer.
He K, Barsoumian HB, Puebla-Osorio N, Hu Y, Sezen D, Wasley MD, Bertolet G, Zhang J, Leuschner C, Yang L, Kettlun Leyton CS, Fowlkes NW, Green MM, Hettrick L, Chen D, Masrorpour F, Gu M, Maazi H, Revenko AS, Cortez MA, Welsh JW. He K, et al. Among authors: sezen d. Cancer Immunol Res. 2023 Apr 3;11(4):486-500. doi: 10.1158/2326-6066.CIR-22-0547. Cancer Immunol Res. 2023. PMID: 36700864 Free PMC article.
Correction: Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy.
He K, Puebla-Osorio N, Barsoumian HB, Sezen D, Rafq Z, Riad TS, Hu Y, Huang A, Voss TA, Kettlun Leyton CS, Schuda LJ, Hsu E, Heiber J, Cortez MA, Welsh JW. He K, et al. Among authors: sezen d. J Exp Clin Cancer Res. 2024 Sep 10;43(1):256. doi: 10.1186/s13046-024-03183-9. J Exp Clin Cancer Res. 2024. PMID: 39256857 Free PMC article. No abstract available.
Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy.
He K, Puebla-Osorio N, Barsoumian HB, Sezen D, Rafiq Z, Riad TS, Hu Y, Huang A, Voss TA, Leyton CSK, Schuda LJ, Hsu E, Heiber J, Cortez MA, Welsh JW. He K, et al. Among authors: sezen d. J Exp Clin Cancer Res. 2024 Sep 2;43(1):251. doi: 10.1186/s13046-024-03165-x. J Exp Clin Cancer Res. 2024. PMID: 39218928 Free PMC article.
NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model.
Barsoumian HB, He K, Hsu E, Bertolet G, Sezen D, Hu Y, Cortez MA, Welsh JW. Barsoumian HB, et al. Among authors: sezen d. Res Sq [Preprint]. 2023 Feb 13:rs.3.rs-2570782. doi: 10.21203/rs.3.rs-2570782/v1. Res Sq. 2023. Update in: Cancer Immunol Immunother. 2023 Sep;72(9):3003-3012. doi: 10.1007/s00262-023-03471-x PMID: 36824846 Free PMC article. Updated. Preprint.
Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy.
Hu Y, Revenko A, Barsoumian H, Bertolet G, Fowlkes NW, Maazi H, Green MM, He K, Sezen D, Voss TA, Leyton CSK, Masrorpour F, Rafiq Z, Puebla-Osorio N, Leuschner C, MacLeod R, Cortez MA, Welsh JW. Hu Y, et al. Among authors: sezen d. J Exp Clin Cancer Res. 2024 Mar 6;43(1):70. doi: 10.1186/s13046-024-02992-2. J Exp Clin Cancer Res. 2024. PMID: 38443968 Free PMC article.
Reirradiation of Pediatric Tumors Using Hypofractionated Stereotactic Radiotherapy.
Gultekin M, Cengiz M, Sezen D, Zorlu F, Yildiz F, Yazici G, Hurmuz P, Ozyigit G, Akyol F, Gurkaynak M. Gultekin M, et al. Among authors: sezen d. Technol Cancer Res Treat. 2017 Apr;16(2):195-202. doi: 10.1177/1533034616655952. Epub 2016 Jul 8. Technol Cancer Res Treat. 2017. PMID: 27352857 Free PMC article.
52 results